# Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation

> **NCT05555641** · PHASE2 · UNKNOWN · sponsor: **Xiaobo Yang, MD** · enrollment: 40 (estimated)

## Conditions studied

- Critical Illness
- Anticoagulation

## Interventions

- **DRUG:** Nafamostat Mesylate
- **DRUG:** Unfractionated Heparin

## Key facts

- **NCT ID:** NCT05555641
- **Lead sponsor:** Xiaobo Yang, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-20
- **Primary completion:** 2024-10-01
- **Final completion:** 2024-10-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05555641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05555641, "Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05555641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*